News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,549 Results
Type
Article (2452)
Company Profile (39)
Press Release (36058)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (14224)
Career Advice (77)
Deals (2086)
Drug Delivery (9)
Drug Development (4124)
Employer Resources (10)
FDA (437)
Job Trends (767)
News (20277)
Policy (1061)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (145)
Allergies (6)
Alliances (3484)
ALS (4)
Alzheimer's disease (46)
Antibody-drug conjugate (ADC) (15)
Approvals (438)
Artificial intelligence (11)
Autoimmune disease (3)
Automation (1)
Bankruptcy (12)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (20)
Cancer (146)
Cardiovascular disease (5)
Career advice (64)
Career pathing (1)
CAR-T (15)
Cell therapy (44)
Cervical cancer (2)
Clinical research (3201)
Collaboration (94)
Compensation (48)
COVID-19 (180)
CRISPR (7)
C-suite (30)
Cystic fibrosis (2)
Data (117)
Denatured (3)
Depression (3)
Diabetes (10)
Diagnostics (464)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (15)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4287)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6107)
Executive appointments (96)
FDA (484)
Featured Employer (3)
Funding (79)
Gene editing (14)
Gene therapy (18)
GLP-1 (61)
Government (150)
Healthcare (708)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (16)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (993)
IRA (7)
Job creations (294)
Job search strategy (62)
Kidney cancer (4)
Labor market (4)
Layoffs (37)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (6)
Management (4)
Manufacturing (19)
MASH (4)
Medical device (312)
Medtech (312)
Mergers & acquisitions (1163)
Metabolic disorders (34)
Multiple sclerosis (8)
Neurodegenerative disease (9)
Neuropsychiatric disorders (3)
Neuroscience (92)
NextGen: Class of 2025 (353)
Non-profit (154)
Northern California (365)
Now hiring (4)
Obesity (16)
Opinion (15)
Ovarian cancer (10)
Pain (9)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (2)
Patents (23)
Patient recruitment (5)
Peanut (1)
People (5702)
Pharmaceutical (5)
Phase I (1387)
Phase II (1609)
Phase III (849)
Pipeline (76)
Policy (12)
Postmarket research (33)
Preclinical (594)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (22)
Real estate (421)
Recruiting (5)
Regulatory (812)
Reports (6)
Research institute (143)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (25)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (359)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (494)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1753)
Vaccines (28)
Venture capitalists (8)
Weight loss (12)
Women's health (1)
Worklife (1)
Date
Today (15)
Last 7 days (47)
Last 30 days (230)
Last 365 days (2550)
2025 (785)
2024 (2621)
2023 (2874)
2022 (3755)
2021 (4057)
2020 (3483)
2019 (2065)
2018 (1559)
2017 (1833)
2016 (1658)
2015 (1869)
2014 (1388)
2013 (1209)
2012 (1425)
2011 (1351)
2010 (1202)
Location
Africa (43)
Alabama (1)
Arizona (15)
Asia (1872)
Australia (301)
California (844)
Canada (134)
China (38)
Colorado (20)
Connecticut (10)
Delaware (4)
Europe (3873)
Florida (44)
Georgia (5)
Idaho (3)
Illinois (14)
India (1)
Indiana (33)
Japan (7)
Kansas (12)
Maryland (25)
Massachusetts (305)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (3)
New Hampshire (2)
New Jersey (69)
New York (49)
North Carolina (90)
Northern California (365)
Ohio (26)
Oklahoma (2)
Oregon (5)
Pennsylvania (50)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (359)
Tennessee (2)
Texas (72)
Utah (2)
Virginia (6)
Washington D.C. (1)
Washington State (52)
Wisconsin (6)
38,549 Results for "enterome bioscience".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Enterome to Participate in the 2024 Jefferies Global Healthcare Conference
Enterome announces that Pierre Bélichard, Enterome’s co-founder and Chief Executive Officer, and Christelle Dumoussaud, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on June 4-6, 2024.
May 30, 2024
·
2 min read
Press Releases
Enterome’s Immunotherapy EO2463 Shows Early Clinical Response in Newly Diagnosed Follicular Lymphoma Suggesting a Potential Alternative to ‘Watchful Waiting’
December 11, 2024
·
6 min read
Press Releases
Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024
December 12, 2024
·
5 min read
Drug Development
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
Enterome announced database lock of its Phase 2 study of EO2401, in combination with an immune checkpoint inhibitor +/- an anti-VEGF therapy, for the treatment of patients with recurrent glioblastoma.
April 17, 2024
·
6 min read
Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024
Enterome announces updated immune-monitoring and clinical data from the ongoing EONHL1-20/SIDNEY trial evaluating EO2463 in monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma.
May 24, 2024
·
7 min read
Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024
Enterome announced that data on its novel OncoMimics™ approach to cancer immunotherapy will be presented in a poster at the upcoming American Association of Cancer Research Annual Meeting, taking place April 5-10 in San Diego, California.
March 6, 2024
·
3 min read
Drug Development
Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma
Enterome today announced updated efficacy data from its Phase 1/2 clinical trial of EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial).
November 20, 2023
·
5 min read
Press Releases
Enterome to Host Webinar on New Clinical Data From the Ongoing Phase 1/2 ‘SIDNEY’ Trial of Lead Programme, EO2463
November 13, 2024
·
4 min read
Press Releases
Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting
November 6, 2024
·
4 min read
Drug Development
Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Enterome announced that clinical data from the ongoing Phase 1/2 trial of EO2463 in monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma will be presented at 2024 American Society of Clinical Oncology Annual Meeting, to take place May 31 - June 4, in Chicago, Illinois.
April 25, 2024
·
3 min read
1 of 3,855
Next
